American Journal of Kidney Diseases
Volume 53, Issue 6 , Pages 1024-1033 , June 2009

Comorbidity and Acute Clinical Events as Determinants of C-Reactive Protein Variation in Hemodialysis Patients: Implications for Patient Survival

  • Sunna Snaedal, MD

      Affiliations

    • Division of Renal Medicine, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden
    • ,
  • Olof Heimbürger, MD, PhD

      Affiliations

    • Division of Renal Medicine, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden
    • ,
  • Abdul Rashid Qureshi, MD, PhD

      Affiliations

    • Baxter Novum, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden
    • ,
  • Anders Danielsson, MD, PhD

      Affiliations

    • Department of Nephrology, Danderyd Hospital, Uppsala, Sweden
    • ,
  • Björn Wikström, MD, PhD

      Affiliations

    • Department of Medical Science, Renal Unit, University Hospital, Uppsala, Sweden
    • ,
  • Bengt Fellström, MD, PhD

      Affiliations

    • Department of Medical Science, Renal Unit, University Hospital, Uppsala, Sweden
    • ,
  • Ingela Fehrman-Ekholm, MD, PhD

      Affiliations

    • Dialysis Unit, Sophiahemmet, Stockholm, Sweden
    • ,
  • Juan Jesús Carrero, PhD

      Affiliations

    • Division of Renal Medicine, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden
    • ,
  • Anders Alvestrand, MD, PhD

      Affiliations

    • Division of Renal Medicine, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden
    • ,
  • Peter Stenvinkel, MD, PhD

      Affiliations

    • Division of Renal Medicine, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden
    • ,
  • Peter Bárány, MD, PhD

      Affiliations

    • Division of Renal Medicine, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden
    • Corresponding Author InformationAddress correspondence to Peter Bárány, MD, PhD, Division of Renal Medicine K56, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Karolinska University Hospital Huddinge, 14186 Stockholm, Sweden

Received 12 September 2008 ,Accepted 12 February 2009.

References 

  1. Parfrey PS, Foley RN. The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol. 1999;10:1606–1615
  2. Davies SJ, Phillips L, Naish PF, Russell GI. Quantifying comorbidity in peritoneal dialysis patients and its relationship to other predictors of survival. Nephrol Dial Transplant. 2002;17:1085–1092
  3. Goodkin DA, Young EW, Kurokawa K, Prutz KG, Levin NW. Mortality among hemodialysis patients in Europe, Japan, and the United States: Case-mix effects. Am J Kidney Dis. 2004;44:16–21
  4. Plantinga LC, Fink NE, Levin NW, et al. Early, intermediate, and long-term risk factors for mortality in incident dialysis patients: The Choices for Healthy Outcomes in Caring for ESRD (CHOICE) Study. Am J Kidney Dis. 2007;49:831–840
  5. Van Manen JG, Korevaar JC, Dekker FW, Boeschoten EW, Bossuyt PM, Krediet RT. Adjustment for comorbidity in studies on health status in ESRD patients: Which comorbidity index to use?. J Am Soc Nephrol. 2003;14:478–485
  6. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2002;62:1524–1538
  7. Stenvinkel P, Pecoits-Filho R, Lindholm B. Coronary artery disease in end-stage renal disease: No longer a simple plumbing problem. J Am Soc Nephrol. 2003;14:1927–1939
  8. Ridker PM, Morrow DA. C-Reactive protein, inflammation, and coronary risk. Cardiol Clin. 2003;21:315–325
  9. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557–1565
  10. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973–979
  11. Kalantar-Zadeh K, Kopple JD, Humphreys MH, Block G. Comparing outcome predictability of markers of malnutrition-inflammation complex syndrome in haemodialysis patients. Nephrol Dial Transplant. 2004;19:1507–1519
  12. Qureshi AR, Alvestrand A, Divino-Filho JC, et al. Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients. J Am Soc Nephrol. 2002;13:S28–S36(suppl 1)
  13. Stenvinkel P, Wanner C, Metzger T, et al. Inflammation and outcome in end-stage renal failure: Does female gender constitute a survival advantage?. Kidney Int. 2002;62:1791–1798
  14. Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis. 2000;35:469–476
  15. Kaysen GA, Dubin JA, Muller HG, Rosales LM, Levin NW. The acute-phase response varies with time and predicts serum albumin levels in hemodialysis patients (The HEMO Study Group). Kidney Int. 2000;58:346–352
  16. Nascimento MM, Pecoits-Filho R, Qureshi AR, et al. The prognostic impact of fluctuating levels of C-reactive protein in Brazilian haemodialysis patients: A prospective study. Nephrol Dial Transplant. 2004;19:2803–2809
  17. Carrero JJ, Qureshi AR, Axelsson J, et al. Comparison of nutritional and inflammatory markers in dialysis patients with reduced appetite. Am J Clin Nutr. 2007;85:695–701
  18. Grambsch P, Therneau T. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81:515–526
  19. Allison P. Survival Analysis Using SAS: A Practical Guide. Cary, NC: SAS Institute; 1995;
  20. Kardys I, Knetsch AM, Bleumink GS, et al. C-Reactive protein and risk of heart failure (The Rotterdam Study). Am Heart J. 2006;152:514–520
  21. Wang AY, Wang M, Woo J, et al. Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients. J Am Soc Nephrol. 2004;15:2186–2194
  22. Panichi V, Maggiore U, Taccola D, et al. Interleukin-6 is a stronger predictor of total and cardiovascular mortality than C-reactive protein in haemodialysis patients. Nephrol Dial Transplant. 2004;19:1154–1160
  23. Honda H, Qureshi AR, Heimburger O, et al. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis. 2006;47:139–148
  24. Bologa RM, Levine DM, Parker TS, et al. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis. 1998;32:107–114
  25. Kimmel PL, Chawla LS, Amarasinghe A, et al. Anthropometric measures, cytokines and survival in haemodialysis patients. Nephrol Dial Transplant. 2003;18:326–332
  26. Tripepi G, Mallamaci F, Zoccali C. Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: Searching for the best risk marker by multivariate modeling. J Am Soc Nephrol. 2005;16:S83–S88(suppl 1)
  27. Girndt M, Kaul H, Sester U, et al. Anti-inflammatory interleukin-10 genotype protects dialysis patients from cardiovascular events. Kidney Int. 2002;62:949–955
  28. Stenvinkel P, Ketteler M, Johnson RJ, et al. IL-10, IL-6, and TNF-alpha: Central factors in the altered cytokine network of uremia—The good, the bad, and the ugly. Kidney Int. 2005;67:1216–1233
  29. Tong M, Carrero JJ, Qureshi AR, et al. Plasma pentraxin 3 in patients with chronic kidney disease: Associations with renal function, protein-energy wasting, cardiovascular disease, and mortality. Clin J Am Soc Nephrol. 2007;2:889–897
  30. van Tellingen A, Grooteman MP, Schoorl M, et al. Intercurrent clinical events are predictive of plasma C-reactive protein levels in hemodialysis patients. Kidney Int. 2002;62:632–638
  31. Bradbury BD, Fissell RB, Albert JM, et al. Predictors of early mortality among incident US hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Clin J Am Soc Nephrol. 2007;2:89–99
  32. Thomson PC, Stirling CM, Geddes CC, Morris ST, Mactier RA. Vascular access in haemodialysis patients: A modifiable risk factor for bacteraemia and death. QJM. 2007;100:415–422
  33. Kaysen GA, Johansen KL, Cheng SC, Jin C, Chertow GM. Trends and outcomes associated with serum albumin concentration among incident dialysis patients in the United States. J Ren Nutr. 2008;18:323–331

 Originally published online as doi:10.1053/j.ajkd.2009.02.008 on April 27, 2009.

PII: S0272-6386(09)00440-5

doi: 10.1053/j.ajkd.2009.02.008

American Journal of Kidney Diseases
Volume 53, Issue 6 , Pages 1024-1033 , June 2009

Article Tools

* Image Usage & Resolution